What is HC Wainwright’s Estimate for AnaptysBio Q1 Earnings?

AnaptysBio, Inc. (NASDAQ:ANAB) – Stock analysts at HC Wainwright lowered their Q1 2026 earnings per share estimates for shares of AnaptysBio in a research note issued to investors on Wednesday, March 4th. HC Wainwright analyst E. Bodnar now forecasts that the biotechnology company will post earnings of ($1.12) per share for the quarter, down from their prior forecast of ($1.02). HC Wainwright has a “Buy” rating and a $66.00 price target on the stock. The consensus estimate for AnaptysBio’s current full-year earnings is ($6.08) per share. HC Wainwright also issued estimates for AnaptysBio’s Q2 2026 earnings at ($1.22) EPS, Q3 2026 earnings at ($1.51) EPS, Q4 2026 earnings at ($1.88) EPS, FY2026 earnings at ($6.52) EPS, FY2027 earnings at ($8.55) EPS, FY2028 earnings at ($3.51) EPS and FY2029 earnings at ($0.61) EPS.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Monday, March 9th. The biotechnology company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $0.89 by $0.69. The firm had revenue of $108.25 million for the quarter, compared to analyst estimates of $87.09 million. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 5.64%.

ANAB has been the topic of a number of other research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of AnaptysBio in a report on Wednesday, January 21st. Guggenheim reissued a “buy” rating on shares of AnaptysBio in a research report on Thursday, December 18th. Wall Street Zen cut shares of AnaptysBio from a “strong-buy” rating to a “buy” rating in a report on Friday, January 23rd. Truist Financial increased their price target on shares of AnaptysBio from $20.00 to $36.00 and gave the stock a “hold” rating in a research note on Monday, November 10th. Finally, UBS Group initiated coverage on shares of AnaptysBio in a research note on Wednesday, January 7th. They set a “buy” rating and a $70.00 price objective on the stock. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, AnaptysBio presently has an average rating of “Moderate Buy” and a consensus target price of $71.89.

AnaptysBio Trading Down 5.4%

NASDAQ:ANAB opened at $57.28 on Friday. AnaptysBio has a 12 month low of $15.32 and a 12 month high of $63.47. The stock has a market cap of $1.65 billion, a price-to-earnings ratio of -110.15 and a beta of 0.32. The company has a 50-day moving average price of $50.17 and a 200-day moving average price of $38.78.

AnaptysBio announced that its Board of Directors has approved a stock buyback program on Friday, November 21st that permits the company to repurchase $100.00 million in shares. This repurchase authorization permits the biotechnology company to reacquire up to 9.6% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s board of directors believes its stock is undervalued.

Insider Activity at AnaptysBio

In other news, CEO Daniel Faga sold 14,281 shares of the business’s stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $44.71, for a total value of $638,503.51. Following the completion of the transaction, the chief executive officer owned 479,344 shares in the company, valued at $21,431,470.24. The trade was a 2.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Dennis Mulroy sold 2,515 shares of the company’s stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $44.71, for a total value of $112,445.65. Following the transaction, the chief financial officer directly owned 21,852 shares in the company, valued at approximately $977,002.92. The trade was a 10.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 156,280 shares of company stock valued at $7,254,939 over the last ninety days. Corporate insiders own 33.50% of the company’s stock.

Hedge Funds Weigh In On AnaptysBio

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd boosted its holdings in shares of AnaptysBio by 940.8% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,530 shares of the biotechnology company’s stock valued at $74,000 after acquiring an additional 1,383 shares during the last quarter. Invesco Ltd. lifted its position in AnaptysBio by 192.6% during the fourth quarter. Invesco Ltd. now owns 124,006 shares of the biotechnology company’s stock valued at $6,012,000 after purchasing an additional 81,625 shares during the period. Mackenzie Financial Corp bought a new position in AnaptysBio during the fourth quarter valued at approximately $1,166,000. XTX Topco Ltd boosted its holdings in AnaptysBio by 113.3% in the fourth quarter. XTX Topco Ltd now owns 38,637 shares of the biotechnology company’s stock worth $1,873,000 after purchasing an additional 20,526 shares during the last quarter. Finally, nVerses Capital LLC purchased a new position in shares of AnaptysBio in the 4th quarter worth $215,000.

Key AnaptysBio News

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: Stifel Nicolaus raised its price target to $85 and reiterated a Buy rating, signaling substantial upside vs. current levels. Stifel Nicolaus price-target raise
• Positive Sentiment: Barclays raised its target to $79 and moved to an Overweight rating, another institutional endorsement that supports upside expectations. Barclays price-target raise
• Positive Sentiment: H.C. Wainwright boosted its target to $66 and kept a Buy rating; the firm’s analyst also published a long‑range FY2030 EPS projection (~$7.67), which is far above current consensus and implies strong optionality from AnaptysBio’s assets. H.C. Wainwright price-target raise HC Wainwright FY2030 note
• Neutral Sentiment: AnaptysBio announced a spin‑off of its biopharma portfolio — a strategic move that can unlock value long term but often creates short‑term uncertainty until details (timing, tax treatment, assets) are disclosed. Spin-off announcement
• Neutral Sentiment: Short‑interest reports show a reported “large increase” but list zero shares and NaN changes — data appears inconsistent and likely not a meaningful signal. (Treat short‑interest data as noisy/uncertain until clarified.)
• Negative Sentiment: Despite positive analyst action, intraday selling and higher-than-average volume suggest profit‑taking or rotation away from a stock that recently traded near its 1‑year high; that technical flow can drive near‑term downside even with favorable analyst commentary.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.